Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October.
Upcoming Medical Conferences:
- An oral presentation highlighting Phase 1/2 results, including cohort 4, for AT-GAA for Pompe disease will be included at the to be held October 1-5, 2019 in Copenhagen, Denmark.
° Oral Platform Presentation: Friday, October 4, 10:00 a.m. CEST (4:00 a.m. ET): First-in-human study of ATB200/AT2221 in patients with Pompe disease: 24-month functional assessment results from the ATB200-02 trial – Benedikt Schoser, MD, Friedrich-Baur Institute, Deptartment of Neurology, Ludwig-Maximilians-University of Munich, Germany.
- A poster presentation highlighting interim clinical results for the first gene therapy in CLN6 Batten disease will be included at the to be held October 23-26, 2019 in Charlotte, NC.
° Poster Sessions: Thursday, October 24, 4:00-5:30 p.m. ET and Friday, October 25, 7:00-8:15 a.m. ET: Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease – Emily de los Reyes, MD, Pediatric Neurologist, Nationwide Children’s Hospital, Columbus, OH. (Poster #204)
Upcoming Investor Conferences:
- John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York, NY on Wednesday, October 2, 2019 at 8:20 a.m. ET.
- Amicus team members and external speakers will present during the Amicus Analyst Day on Thursday, October 10, 2019 in New York, NY at 8:30 a.m. ET.
A live audio webcast of the presentations during the investor conferences and Amicus Analyst Day can be accessed via the Investors section of the Amicus Therapeutics corporate website at , and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at , and follow on and .
CONTACTS:
Investors:
Amicus Therapeutics
Sara Pellegrino, IRC
Vice President, Investor Relations
(609) 662-5044
Media:
Christopher Byrne
Executive Director, Corporate Communications
609-662-2798
FOLD–G
